Articles avec mandats d'accès public - Marcela V MausEn savoir plus
Non disponibles : 8
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
BD Choi, X Yu, AP Castano, AA Bouffard, A Schmidts, RC Larson, ...
Nature biotechnology 37 (9), 1049-1058, 2019
Exigences : US National Institutes of Health, Damon Runyon Cancer Research Foundation
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours
RC Larson, MC Kann, SR Bailey, NJ Haradhvala, PM Llopis, AA Bouffard, ...
Nature 604 (7906), 563-570, 2022
Exigences : US National Institutes of Health, Damon Runyon Cancer Research Foundation
Toward better understanding and management of CAR-T cell–associated toxicity
A Schmidts, M Wehrli, MV Maus
Annual Review of Medicine 72 (1), 365-382, 2021
Exigences : Fonds national suisse, US National Institutes of Health
Case 35-2019: a 66-year-old man with pancytopenia and rash
MV Maus, MB Leick, KM Cornejo, V Nardi
New England Journal of Medicine 381 (20), 1951-1960, 2019
Exigences : US National Institutes of Health
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics
F Korell, ML Olson, D Salas-Benito, MB Leick, RC Larson, A Bouffard, ...
Science Translational Medicine 16 (750), eadk7640, 2024
Exigences : Fonds national suisse
Genetic retargeting of E3 ligases to enhance CAR T cell therapy
IC Lane, G Kembuan, J Carreiro, MC Kann, W Lin, AA Bouffard, J Kreuzer, ...
Cell Chemical Biology 31 (2), 338-348. e5, 2024
Exigences : US National Institutes of Health
Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy
ZE Walton, MJ Frigault, MV Maus
Expert Opinion on Pharmacotherapy 25 (3), 263-279, 2024
Exigences : US National Institutes of Health
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology
GJ Kembuan, JY Kim, MV Maus, M Jan
Trends in Cancer, 2024
Exigences : US National Institutes of Health
Disponibles quelque part : 116
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
DW Lee, BD Santomasso, FL Locke, A Ghobadi, CJ Turtle, JN Brudno, ...
Biology of blood and marrow transplantation 25 (4), 625-638, 2019
Exigences : US National Institutes of Health
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
DM O’Rourke, MLP Nasrallah, A Desai, JJ Melenhorst, K Mansfield, ...
Science translational medicine 9 (399), eaaa0984, 2017
Exigences : US National Institutes of Health
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma
N Raje, J Berdeja, YI Lin, D Siegel, S Jagannath, D Madduri, M Liedtke, ...
New England Journal of Medicine 380 (18), 1726-1737, 2019
Exigences : US National Institutes of Health, US Department of Veterans Affairs
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
GP Linette, EA Stadtmauer, MV Maus, AP Rapoport, BL Levine, L Emery, ...
Blood, The Journal of the American Society of Hematology 122 (6), 863-871, 2013
Exigences : US National Institutes of Health
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
MV Maus, SA Grupp, DL Porter, CH June
Blood, The Journal of the American Society of Hematology 123 (17), 2625-2635, 2014
Exigences : US National Institutes of Health
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies
GL Beatty, AR Haas, MV Maus, DA Torigian, MC Soulen, G Plesa, ...
Cancer immunology research 2 (2), 112-120, 2014
Exigences : US National Institutes of Health
Recent advances and discoveries in the mechanisms and functions of CAR T cells
RC Larson, MV Maus
Nature Reviews Cancer 21 (3), 145-161, 2021
Exigences : US National Institutes of Health, Damon Runyon Cancer Research Foundation
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans
MV Maus, AR Haas, GL Beatty, SM Albelda, BL Levine, X Liu, Y Zhao, ...
Cancer immunology research 1 (1), 26-31, 2013
Exigences : US National Institutes of Health
Chimeric antigen receptor T cells against CD19 for multiple myeloma
AL Garfall, MV Maus, WT Hwang, SF Lacey, YD Mahnke, JJ Melenhorst, ...
New England Journal of Medicine 373 (11), 1040-1047, 2015
Exigences : US National Institutes of Health
Engineered CRISPR–Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing
BP Kleinstiver, AA Sousa, RT Walton, YE Tak, JY Hsu, K Clement, ...
Nature biotechnology 37 (3), 276-282, 2019
Exigences : Bill & Melinda Gates Foundation, US National Institutes of Health, Conseil …
Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication
CC Kloss, J Lee, A Zhang, F Chen, JJ Melenhorst, SF Lacey, MV Maus, ...
Molecular therapy 26 (7), 1855-1866, 2018
Exigences : US National Institutes of Health
Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery
L Tang, Y Zheng, MB Melo, L Mabardi, AP Castaño, YQ Xie, N Li, ...
Nature biotechnology 36 (8), 707-716, 2018
Exigences : Fonds national suisse, US National Institutes of Health, A*Star, Singapore
Les informations concernant la publication et le financement sont déterminées automatiquement par un programme informatique